AU2017214572A1 - Glucose conjugates of triptolide, analogs and uses thereof - Google Patents

Glucose conjugates of triptolide, analogs and uses thereof Download PDF

Info

Publication number
AU2017214572A1
AU2017214572A1 AU2017214572A AU2017214572A AU2017214572A1 AU 2017214572 A1 AU2017214572 A1 AU 2017214572A1 AU 2017214572 A AU2017214572 A AU 2017214572A AU 2017214572 A AU2017214572 A AU 2017214572A AU 2017214572 A1 AU2017214572 A1 AU 2017214572A1
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
cancer
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017214572A
Other languages
English (en)
Inventor
Qingli HE
Jun Liu
ll Minn
Martin G. Pomper
Qiaoling WANG
Biao Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2017214572A1 publication Critical patent/AU2017214572A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AU2017214572A 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof Abandoned AU2017214572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291416P 2016-02-04 2016-02-04
US62/291,416 2016-02-04
PCT/US2017/016527 WO2017136739A1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Publications (1)

Publication Number Publication Date
AU2017214572A1 true AU2017214572A1 (en) 2018-08-16

Family

ID=59500284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017214572A Abandoned AU2017214572A1 (en) 2016-02-04 2017-02-03 Glucose conjugates of triptolide, analogs and uses thereof

Country Status (8)

Country Link
US (2) US10695319B2 (cg-RX-API-DMAC7.html)
EP (1) EP3411121B1 (cg-RX-API-DMAC7.html)
JP (1) JP7042744B2 (cg-RX-API-DMAC7.html)
CN (1) CN108601952B (cg-RX-API-DMAC7.html)
AU (1) AU2017214572A1 (cg-RX-API-DMAC7.html)
CA (1) CA3013619A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018009406A (cg-RX-API-DMAC7.html)
WO (1) WO2017136739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体(上海)有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN111500467B (zh) * 2019-03-28 2021-11-02 中国医学科学院医药生物技术研究所 一种制备抗丙型肝炎病毒活性化合物雷斯吲哚甲的海洋青霉菌
JP7353500B2 (ja) 2019-12-30 2023-09-29 グゥアンドン プロビンシャル ホスピタル オブ ティーシーエム アクリル酸トリプトリド、その調製方法および用途
CN111040018A (zh) * 2019-12-30 2020-04-21 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 丙烯酸雷公藤甲素酯、其制备方法及其应用
CN115715201A (zh) * 2020-03-02 2023-02-24 约翰霍普金斯大学 葡萄糖雷公藤甲素缀合物及其用途
EP4200022A1 (en) * 2020-08-21 2023-06-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115286684A (zh) * 2022-05-20 2022-11-04 福建医科大学 一种糖与雷公藤内酯醇或其衍生物的缀合物及其制备方法与应用
WO2024186319A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer
AU2025207356A1 (en) 2024-01-11 2026-08-06 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218367B1 (en) * 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
EP1390358A4 (en) * 2001-03-15 2004-06-16 Pharmagenesis Inc AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICROPHES
US9150600B2 (en) * 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs

Also Published As

Publication number Publication date
JP2019509986A (ja) 2019-04-11
MX2018009406A (es) 2018-11-09
US20200297693A1 (en) 2020-09-24
US10695319B2 (en) 2020-06-30
CN108601952A (zh) 2018-09-28
WO2017136739A1 (en) 2017-08-10
US20190038596A1 (en) 2019-02-07
EP3411121A1 (en) 2018-12-12
CA3013619A1 (en) 2017-08-10
EP3411121B1 (en) 2024-09-11
EP3411121A4 (en) 2019-12-18
JP7042744B2 (ja) 2022-03-28
CN108601952B (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
EP3411121B1 (en) Glucose conjugates of triptolide, analogs and uses thereof
Nakada et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
JP7103953B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
JP6557744B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2019529444A5 (cg-RX-API-DMAC7.html)
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
JP2015527318A5 (cg-RX-API-DMAC7.html)
JP2019504100A5 (cg-RX-API-DMAC7.html)
JP2019509986A5 (cg-RX-API-DMAC7.html)
JP2019524713A5 (cg-RX-API-DMAC7.html)
WO2017136731A1 (en) Rapaglutins, novel inhibitors of glut and use thereof
ES2788390T3 (es) Composición médica que comprende un compuesto heterocíclico de diamino-carboxamida como principio activo
JP2023534292A5 (cg-RX-API-DMAC7.html)
RU2016119491A (ru) Конъюгаты антитела к efna4 с лекарственным средством
TWI615145B (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
CN108498518B (zh) 七元环小檗碱类似物及其药物组合物在制备治疗多发性骨髓瘤的药物中的应用
JPWO2022019259A5 (cg-RX-API-DMAC7.html)
JP6488280B2 (ja) タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
CN111773388A (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
KR20170091610A (ko) 신규 peg 유도체
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
RU2021133713A (ru) Adc для лечения сопутствующе с или после доцетаксела
HK1240958A1 (en) Peg derivative
MY144013A (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
CN102370986A (zh) 含羟甲基酞胺哌啶酮衍生物的药物组合物及其制备和应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LIU, JUN; HE, QINGLI; POMPER, MARTIN G.; MINN, LL; YU, BIAO AND WANG, QIAOLING

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application